{"name":"Xichun Hu","slug":"xichun-hu","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQd1BIVzYzdWdsSHZSYUNNTV9CVHNMT09YNmVDeGlpUVFBbUpzSkEwckJTTVEwOEZZUkItWElxNnJrcjFGQnpVaDd5S19QVVFRMEJNcUhoVXBsVmxmZVp2R0djVWYtTEI0cWltWFdrNUpSSEhDdXV0MmhSeFBjMnRYblpGbGVoeTJwUVZ1dTFXVFpncXRWNUtoSmRJa1FnQQ?oc=5","date":"2025-08-14","type":"pipeline","source":"Medscape","summary":"Tibremciclib for Advanced Breast Cancer: Is It Worth It? - Medscape","headline":"Tibremciclib for Advanced Breast Cancer: Is It Worth It?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1HT3lvQTdvMF9JaXFuSzlpaWtLOTJoN0tHWFh0OTJXZ3EwdXd6d293dHlLY0t5dE16dkpSaTNtVWNqSEZJQkxfNGtTVXlpN3NVZ1VsQjdKZ1VvQ0FLV0tB?oc=5","date":"2024-09-12","type":"trial","source":"nature.com","summary":"First-in-human study of DP303c, a HER2-targeted antibody-drug conjugate in patients with HER2 positive solid tumors - nature.com","headline":"First-in-human study of DP303c, a HER2-targeted antibody-drug conjugate in patients with HER2 positive solid tumors","sentiment":"positive"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}